Current Unmet Needs in ccRCC Diagnosis

EP: 1.The Evolvement of Imaging in ccRCC

EP: 2.The Biggest Challenges in Distinguishing ccRCC From Benign Renal Masses

EP: 3.Strengths and Weaknesses of Imaging Modalities in ccRCC

EP: 4.Treatment or Lack of Treatment of Small Renal Masses

EP: 5.Decision-Making in Small Renal Masses

Now Viewing

EP: 6.Current Unmet Needs in ccRCC Diagnosis

EP: 7.Early Detection of ccRCC

EP: 8.Key Benefits of PET in ccRCC Risk Stratification

EP: 9.The ZIRCON Trial

EP: 10.The MOA of TLX250

EP: 11.Top-Line Results of the Phase 3 ZIRCON Study

EP: 12.Risk Stratification in ccRCC: The Impact in Patient Populations

EP: 13.Lymph Node–Positive Kidney Disease: Future Implications of PET Imaging

EP: 14.Overcoming Challenges for Wider Adoption of TLX250

EP: 15.The Future of PET Imaging Agents

EP: 16.The Logistical Challenges in ccRCC Treatment

Current Gaps in Renal Mass Imaging

Main Discussion Topics:

• Current imaging cannot reliably predict tumor biology or aggressiveness.
• Need for imaging techniques that can identify aggressive lesions requiring immediate intervention
• Comparison to advances in prostate cancer with molecular imaging (prostate-specific membrane antigen [PSMA] PET)
• Desire for similar molecular imaging paradigms in kidney cancer

Key Points for Physicians:

• Contemporary imaging provides anatomic and enhancement information but limited biological insights.
• The ability to predict which tumors will become aggressive remains a significant gap.
• Prostate cancer imaging has evolved to routinely include molecular imaging (PSMA PET).
• Similar developments are needed in kidney cancer imaging.

Notable Insights:

There is a significant need for imaging that predicts biological behavior rather than just providing anatomic information.

Clinical Significance:

Developing imaging that predicts tumor biology could prevent overtreatment of indolent tumors and ensure appropriate intervention for aggressive ones.